Abstract
At present, pembrolizumab is the first-line standard treatment for recurrent/ metastatic head and neck squamous cell carcinoma(R/M HNSCC). According to existing studies, it is found that the combination of multi-target kinase inhibitor and pembrolizumab has a good objective response rate. There is great need to explore the efficacy of pembrolizumab in combination with anlotinib in the first-line treatment for patients with R/M HNSCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
